Advertisement
Editorial| Volume 48, ISSUE 6, P433-435, September 15, 2000

Download started.

Ok

On clinical trials in psychiatry

      The randomized controlled clinical trial is still a relatively new technology for assessing therapeutic interventions, yet innovations in the design and analysis of clinical trials in psychiatry have lagged behind other areas of the biomedical sciences. This delay in the advancement of the science and practice of psychiatric clinical trials is due in part to the inability, dating back to the 1950s, to solve the problem of the unreliability of psychiatric diagnosis and to the inability of psychiatric researchers to develop common agreed-upon outcome measures. Even though advances have been made in diagnosis and measurement, the existence of these and other methodological problems continues to contribute to the limited success of acute-phase efficacy trials in psychiatry. For example, in depression,
      • Thase M.E.
      How should efficacy be evaluated in randomized clinical trials of treatments for depression?.
      notes that
      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      Subscribe:

      Subscribe to Biological Psychiatry
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect

      References

        • Brophy J.M.
        • Joseph L.
        Placing trials in context using Bayesian analysis. GUSTO revisited by Reverend Bayes.
        JAMA. 1995; 273: 871-875
        • Goodman S.N.
        Toward evidence-based medical statistics. 1.
        Ann Intern Med. 1999; 130: 995-1004
        • Goodman S.N.
        Toward evidence-based medical statistics. 2.
        Ann Intern Med. 1999; 130: 1005-1013
        • Greenhouse J.
        On some applications of Bayesian methods in cancer clinical trials.
        Stat Med. 1992; 11: 37-53
        • Greenhouse J.
        • Stangl D.
        • Kupfer D.
        • Prien R.
        Methodological issues in maintenance therapy clinical trials.
        Arch Gen Psychiatry. 1991; 48: 313-318
        • Greenhouse J.
        • Wasserman L.
        Robust Bayesian analysis of clinical trials.
        Stat Med. 1995; 14: 1379-1391
        • Hyman S.
        • Shore D.
        An NIMH perspective on the use of placebos.
        Biol Psychiatry. 2000; 47: 689-691
        • Lavori P.W.
        • Dawson R.
        • Rush A.J.
        Flexible treatment strategies in chronic disease.
        Biol Psychiatry. 2000; 48: 605-614
      1. Norquist G, Lebowitz B, Hyman S. Expanding the frontier of treatment research. Available at: http://journals.apa.org/prevention/volume2/pre0020001a.html. Accessed July 29, 2000.

        • Rush A.J.
        • Post R.M.
        • Nolen W.A.
        • Keck Jr, P.E.
        • Suppes T.
        • Altshuler L.
        • McElroy S.L.
        Methodological issues in developing new acute treatments for patients with bipolar illness.
        Biol Psychiatry. 2000; 48: 615-624
        • Speigelhalter D.J.
        • Freedman L.S.
        • Parmar M.K.B.
        Bayesian approaches to randomized trials.
        J R Stat Soc A. 1994; 157: 357-416
        • Thase M.E.
        How should efficacy be evaluated in randomized clinical trials of treatments for depression?.
        J Clin Psychiatry. 1999; 60: 23-31
      2. U.S. Government Accounting Office (1994): Breast Conservation versus Mastectomy: Patient Survival in Day-to-Day Medical Practice and in Randomized Studies, PEMD-95-9. Washington, DC: U.S. Government Accounting Office.